This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
by Kinjel Shah
Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
by Kinjel Shah
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Viking Therapeutics, Inc. (VKTX) Stock Slides as Market Rises: Facts to Know Before You Trade
by Zacks Equity Research
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $23.91, marking a -0.99% move from the previous day.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $29.73, denoting a +0.61% change from the preceding trading day.
NVO Stock Slips 4% as Roche Inks Obesity Drug Deal With Zealand
by Zacks Equity Research
With Roche's latest deal, a new contender enters the obesity space, which could threaten NVO and LLY's dominance in the market.
Sage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Sage Therapeutics (SAGE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply
by Zacks Equity Research
The deal provides Viking Therapeutics with a secured dedicated annual supply of both injectable and oral versions of its obesity drug VK2735.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
by Zacks Equity Research
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous trading day.
Novo Nordisk Plunges 21% in 3 Months: Buy, Sell or Hold the Stock?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to retain in one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
ABBV Enters Obesity Bandwagon, Inks $2.2B Licensing Deal for Amylin Drug
by Zacks Equity Research
Per the terms of the deal, AbbVie will lead the development and commercialization of the obesity drug developed by Gubra.
Viking Therapeutics, Inc. (VKTX) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
PRGO's fourth-quarter top line is likely to have benefited from higher net price realization for its products through strategic price increases.
Should You Buy VKTX Stock Amid Renewed M&A Speculations?
by Sundeep Ganoria
Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics, regardless of buyout speculations.
What's in the Cards for Viatris Stock This Q4 Earnings?
by Zacks Equity Research
VTRS' Q4 results are likely to gain from new product launches in all major geographies.
ADMA Biologics Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On ADMA's fourth-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
BioMarin to Report Q4 Earnings: Here's What to Expect
by Zacks Equity Research
When BMRN reports fourth-quarter earnings, investors will likely focus on the sales performance of its dwarfism drug Voxzogo.
LLY Rises More Than 4% in a Week: How to Play the Stock
by Kinjel Shah
Though Eli Lilly stock looks quite expensive, we suggest investors hold on to it as it still has robust growth prospects.
VKTX's Q4 Loss Wider Than Expected, Sales Nil, Stock Down 10%
by Zacks Equity Research
Viking Therapeutics' fourth-quarter earnings miss estimates. The decline in stock price was attributable to a lack of material updates on its pipeline.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?